Nijhawan Pardeep 4

What Happened Pardeep Nijhawan, Chief Executive Officer of Edesa Biotech (EDSA), made open-market purchases and received a grant reported on a Form 4 filed March 2, 2026. He purchased a total of 50,571 shares in two open-market transactions (20,571 shares and 30,000 shares) for a combined reported cash outlay of $99,176. He also was granted 10,016 restricted share units (RSUs) that vested in full upon grant (reported with $0 acquisition price).

Key Details

• Transactions reported: purchases on 2026-02-26 and 2026-02-27; RSU grant on 2026-03-02 (filed 2026-03-02).
• Purchases:
  • 20,571 shares on 2026-02-26 at a weighted average $1.58 (total $32,480). Prices ranged $1.54–$1.58 (footnote F1).
  • 30,000 shares on 2026-02-27 at a weighted average $2.22 (total $66,696). Prices ranged $2.22–$2.2295 (footnote F3).
• Award: 10,016 RSUs on 2026-03-02, reported at $0.00 and noted as vested in full upon grant under the 2019 Equity Incentive Plan (footnote F2).
• Shares owned after these transactions: not specified in this filing.
• Other disclosures: Mr. Nijhawan reports certain corporate and trust entities (footnotes F4 and F5) and disclaims beneficial ownership of shares held by those entities except to the extent of his pecuniary interest.

Context

• These are outright purchases (a bullish signal in that the insider bought shares) and an equity award that vested immediately. The RSU grant is reported at $0.00 in the filing but represents an issuance of shares under the company plan; the filing does not assign a cash value in Column 4.
• No sale transactions were reported in this filing. The filing does not indicate any 10b5-1 trading plan or tax-withholding share-forfeiture events.
• Retail investors often view insider purchases as more informative than awards; this filing documents modest open-market buying by the CEO totaling about $99K.